Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
ESMO: Merck and Moderna post phase 3 cancer vaccine data early
While the primary endpoint hit approached analysts’ best-case scenario, the result was tempered by weaker-than-expected data on a secondary endpoint.
Nick Paul Taylor
,
Fraiser Kansteiner
Oct 22, 2026 4:45pm
AbbVie posts phase 3 HS win but falls short of expectations
Oct 22, 2026 10:39am
Roche builds blockbuster case in MS as FDA decision approaches
Oct 21, 2026 9:30am
Disc spins past FDA setback with ‘overwhelmingly positive’ data
Oct 19, 2026 8:00am
Vanda pauses social anxiety program after failing phase 3 trial
Oct 15, 2026 2:25am
Merck KGaA spinout iOnctura touts PI3K inhibitor in eye cancer
Oct 14, 2026 1:42pm